2019
Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma
Guerra MT, Florentino RM, Franca A, Lima Filho AC, Dos Santos ML, Fonseca RC, Lemos FO, Fonseca MC, Kruglov E, Mennone A, Njei B, Gibson J, Guan F, Cheng YC, Ananthanarayanan M, Gu J, Jiang J, Zhao H, Lima CX, Vidigal PT, Oliveira AG, Nathanson MH, Leite MF. Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma. Gut 2019, 68: 1676. PMID: 31315892, PMCID: PMC7087395, DOI: 10.1136/gutjnl-2018-317811.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsApoptosisCalcium SignalingCarcinogenesisCarcinoma, HepatocellularCell ProliferationCells, CulturedDNA MethylationFemaleGene Expression Regulation, NeoplasticHepatocytesHumansInositol 1,4,5-Trisphosphate ReceptorsLiverLiver NeoplasmsLiver RegenerationMaleMice, KnockoutMiddle AgedSurvival AnalysisConceptsChronic liver diseaseITPR3 expressionLiver cancer cellsLiver diseaseMouse modelFinal common eventCancer cellsSpecimens of patientsIndependent patient cohortsControl liver specimensHuman HCC cellsType 3 InsP3 receptorHuman liver samplesIncreased expression levelCancer deathPatient cohortCommon molecular eventPoor survivalHepatocellular carcinomaLiver specimensNormal liverHCC cellsAbstractTextHCCType 3 isoformEffects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis
Kaplan DE, Serper M, Mehta R, Fox R, John B, Aytaman A, Baytarian M, Hunt K, Albrecht J, Njei B, Taddei TH, Group V. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology 2019, 156: 1693-1706.e12. PMID: 30660733, DOI: 10.1053/j.gastro.2019.01.026.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularCholesterolFemaleHeart FailureHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaLiver CirrhosisLiver NeoplasmsMaleMiddle AgedMyocardial InfarctionPropensity ScoreProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesStrokeSurvival RateUnited StatesConceptsRetrospective cohort studyStatin exposureLarge national cohortHepatic decompensationStatin useCohort studyHazard ratioNational cohortMultivariable Cox proportional hazards modelsCox proportional hazards modelBaseline total cholesterolPrior statin exposureStatin-naïve subjectsEffect of hypercholesterolemiaVeterans Health AdministrationProportional hazards modelHepatocellular carcinoma developmentDecrease of mortalityRisk-set matchingChild-TurcottePugh classStatin therapyDL increaseTotal cholesterolHepatic function
2018
Bariatric Surgery and Hepatocellular Carcinoma: a Propensity Score-Matched Analysis
Njei B, McCarty TR, Sharma P, Lange A, Najafian N, Ngu JN, Ngomba VE, Echouffo-Tcheugui JB. Bariatric Surgery and Hepatocellular Carcinoma: a Propensity Score-Matched Analysis. Obesity Surgery 2018, 28: 3880-3889. PMID: 30069863, PMCID: PMC6219901, DOI: 10.1007/s11695-018-3431-5.Peer-Reviewed Original ResearchMeSH KeywordsBariatric SurgeryCarcinoma, HepatocellularCross-Sectional StudiesHumansLiver NeoplasmsObesity, MorbidPropensity ScoreConceptsBariatric surgeryHepatocellular carcinomaPrevalence ratiosOdds ratioLow prevalenceUnited States Nationwide Inpatient Sample databaseNationwide Inpatient Sample databaseOccurrence of HCCPropensity scorePrior bariatric surgeryHospital mortality rateMorbidly obese patientsAge-adjusted prevalenceMortality odds ratioRisk of deathLength of stayCross-sectional associationsHospital mortalityMorbid obesityBaseline characteristicsObese patientsSecondary outcomesBackgroundThe associationPrimary outcomePatient mortality
2017
Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease
Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non‐alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2017, 46: 1061-1069. PMID: 28960360, DOI: 10.1111/apt.14342.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseFatty liver diseaseLarger tumor sizeLiver diseaseHCC etiologyCurative intentNAFLD-HCCCurative treatmentTumor sizeMetastatic HCCCardiovascular diseaseHepatocellular carcinomaDecompensated liver diseaseWorse median survivalAbsence of cirrhosisSignificant survival differenceDiagnosis of HCCLess cirrhosisNAFLD groupMedian survivalWorse survivalFavorable survivalIndependent predictorsLiver cirrhosisHCC group
2016
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis
Njei B, McCarty TR, Fortune BE, Lim JK. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost‐effectiveness analysis. Alimentary Pharmacology & Therapeutics 2016, 44: 1090-1101. PMID: 27640785, DOI: 10.1111/apt.13798.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsBenzimidazolesCarcinoma, HepatocellularCost-Benefit AnalysisDisease ProgressionDrug Therapy, CombinationFluorenesGenotypeHepacivirusHepatitis CHumansLiver CirrhosisLiver NeoplasmsLiver TransplantationNeoplasm Recurrence, LocalQuality-Adjusted Life YearsRibavirinSofosbuvirUnited StatesConceptsHepatitis C virusLiver transplantationTime of transplantHCV recurrencePost-LTCost-effective strategyTreatment of HCVEnd-stage liver disease (MELD) scoreOptimal timingDonor LT recipientsLiver Disease scoreHCV genotype 1Hepatitis C therapyMarkov state transition modelHepatocellular carcinoma casesBase-case analysisSeparate treatment strategiesCost-effectiveness analysisAllograft failureDecompensated diseaseOngoing viraemiaPre-LTHCV treatmentLT recipientsMELD score
2015
Emerging trends in hepatocellular carcinoma incidence and mortality
Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015, 61: 191-199. PMID: 25142309, PMCID: PMC4823645, DOI: 10.1002/hep.27388.Peer-Reviewed Original ResearchConceptsIB mortalityHCC incidenceHepatocellular carcinomaIncidence of HCCMultivariable Cox regression analysisOverall median survivalCox regression analysisEnd Results (SEER) dataSignificant survival improvementAge-adjusted incidenceU.S. populationHepatocellular carcinoma incidenceJoinpoint Regression ProgramIncidence-based mortalityRegression analysisSignificant increaseCurative modalityLiver transplantCurative stageMedian survivalSurvival improvementCarcinoma incidenceTumor sizeVascular invasionPrimary tumor
2014
Long-term Survival of Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma
Njei B. Long-term Survival of Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma. Journal Of Clinical Gastroenterology 2014, 48: 385-386. PMID: 24440939, PMCID: PMC4822547, DOI: 10.1097/mcg.0000000000000070.Peer-Reviewed Original Research